ALAS2 Antibody

1. we report that the dynamics of ALAS2 active site loop is anti-correlated with the dynamics of the C-terminal tail and that this anti-correlation can represent a molecular basis for the functional and dynamic asymmetry of the ALAS2 homodimer. PMID: 29958424
2. report confirms the considerable variability in manifestations among patients with ALAS2 or SLC25A38 mutations and draws attention to differences in the assessment and the monitoring of iron overload and its complications PMID: 28772256
3. A novel ALAS2 missense mutation in exon 9 affects the enzymatic activity of ALAS2 by affecting its interaction with the cofactor pyridoxal 5'-phosphate in X-linked sideroblastic anemia. PMID: 28667034
4. a case of X-linked sideroblastic anemia caused by a novel homozygous deletional mutation in exon 10 of ALAS2 gene is presented PMID: 28731922
5. int-1-GATA site should be examined in patients with XLSA in clinical settings when no known mutation is found in ALAS2 exons. PMID: 28123038
6. From pH jump experiments, comparable rates for the denaturation of the tertiary structure and PLP-microenvironment were discerned, indicating that the catalytic active site geometry strongly depends on the stable tertiary structural organization. Lastly, we demonstrate that partially folded ALAS tends to self-associate into higher oligomeric species at moderate GuHCl concentrations. PMID: 27751851
7. data indicate that the X-linked protoporphyria variants possess enhanced ALAS activity and ALA dissociation rates, as well as distinct structural properties from those of wild-type hALAS PMID: 26300302
8. In this article we add a novel mutation to the previously described 61 different ALAS2 mutations identified in X-linked sideroblastic anaemia patients. PMID: 24829177
9. the primary deficiency in ferrochelatase leads to a secondary increase in ALAS2 expression. PMID: 25179834
10. The ALAS2 Y365C mutation impairs pyridoxal 5'-phosphate binding to ALAS2, destabilizing the enzyme. X inactivation was not highly skewed in WBC from affected women. This X-linked dominant mutation perturbs erythropoiesis via cell-nonautonomous effects. PMID: 25705881
11. the 130-base pair enhancer region located in the first intron of the ALAS2 gene should be examined in patients with congenital sideroblastic anemia in whom the gene responsible is unknown. PMID: 23935018
12. 5 families with X-linked sideroblastic anemia had mutations in a GATA transcription factor binding site located in a transcriptional enhancer element in intron 1 of the ALAS2 gene. PMID: 24166784
13. Loss-of-function FECH and gain-of-function erythroid-specific ALAS2 mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. PMID: 23364466
14. ALAS2 gain-of-function mutations increas the specific activity (DeltaAT, DeltaAGTG and p.Q548X) or stability (DeltaG) of the enzyme, thereby leading to the increased erythroid protoporphyrin accumulation causing X-linked protoporphyria. PMID: 23348515
15. A large gain-of-function domain within the C-terminus of ALAS2 is associated with X-linked dominant protoporphyria. PMID: 23263862
16. Late-onset photosensitivity was caused by ALAS2 mutation in a family with dominant protoporphyria. PMID: 23223129
17. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the beta-subunit of succinyl-CoA synthetase (SUCLA2). PMID: 22740690
18. the C-terminal region of ALAS2 protein may function as an intrinsic modifier that suppresses catalytic activity and increases the degradation of its protein, each function of which is enhanced by the Met567Ile mutation and Val562Ala mutation, respectively PMID: 22269113
19. Data suggest that ALAS2 gene mutations should be considered not only as causative of X-linked sideroblastic anemia (XLSA) and XLDPP but may also modulate gene function in other erythropoietic disorders. PMID: 21653323
20. identification of five probands with sideroblastic anemia and ALAS2 R452S (due to SNP); all were African-American males; all presented with moderate anemia; the four adults presented with iron overload [a multi-case report from the United States] PMID: 21800356
21. Thirteen different ALAS2 mutations were identified in 16 out of 29 probands with sideroblastic anemia. PMID: 21309041
22. We found the previously published R452H and R452C ALAS2 mutations in 3 patients with X-linked sideroblastic anemia PMID: 21252495
23. HIF1-mediated ALAS2 upregulation promotes erythropoiesis to satisfy the needs of an organism under hypoxic conditions. PMID: 21207956
24. About 4% of unrelated EPP patients have X-linked dominant protoporphyria (MIM 300752) caused by gain-of-function mutations in the ALAS2 gene leading to an increased erythroid heme biosynthesis & protoporphyrin accumulation. Review. PMID: 20850938
25. Seven ALAS2 mutations were detected in eight sporadic CSA cases, two being novel: V301A in a male patient and R517G in a female patient PMID: 19731322
26. A novel mutation in exon 5 of the ALAS2 gene results in X-linked sideroblastic anemia. PMID: 12031592
27. A C to G transversion at nucleotide -206 from the transcription start site was found in the proximal promoter region of ALAS2 in X-linked sideroblastic anemia. The region of the mutation may bind a novel and important erythroid regulatory element. PMID: 12663458
28. the major splice isoform of ALAS2 is functional in vivo and could significantly contribute to erythroid heme biosynthesis and hemoglobin formation PMID: 14643893
29. there is nucleotide variation at Msn and Alas2 on the X chromosome PMID: 15166166
30. sequence identity of ALAS from Rhodobacter capsulatus and human eALAS is 49% PMID: 16121195
31. ALAS2 mutations might contribute to more severe iron loading in persons with primary hemochromatosis. PMID: 16446107
32. upon the NaBu stimulation, binding of Sp1 protein to ALAS2 promoter increased significantly, with concurrent increases in acetylation level of histone H3 and dimethylation level of H3-Lysine4 at ALAS2 promoter PMID: 18555711
33. An impact of ALAD2 on blood lead levels or hemoglobin was not seen in Romanian women from a lead-contaminated region. PMID: 18569569
34. gain-of-function mutations in ALAS2 cause a previously unrecognized form of porphyria, X-linked dominant protoporphyria, characterized biochemically by a high proportion of zinc-protoporphyrin in erythrocytes PMID: 18760763
35. Multi-organ iron overload in an African-American man with ALAS2 R452S and SLC40A1 R561G. PMID: 19066423
36. Hypoxia induces erythroid-specific 5-aminolevulinate synthase expression in human erythroid cells through transforming growth factor-beta signaling. PMID: 19187226

顯示更多

收起更多

HGNC: 397

OMIM: 300751

KEGG: hsa:212

STRING: 9606.ENSP00000332369

UniGene: Hs.522666